CD81

Across TCGA pan-cancer cohorts, CD81 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated CD81 data layer compared with 24 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher CD81 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated CD81 expression acts as an unfavorable survival marker, although some lineages such as LUAD show a favorable association.

CCRCC, PDAC, and HNSC are the cancer types where CD81 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Quartile	All	0.583	0.965	<.001	19	view →
PDAC	OS	Tertile	III,IV	0.197	0.637	.003	13	view →
HNSC	DFS	Median	II,III,IV	0.897	0.991	.004	8	view →
LSCC	DFS	Median	All	0.894	0.978	.013	7	view →
LUAD	OS	Quartile	III,IV	0.815	0.390	.019	5	view →
GBM	OS	Tertile	All	0.240	0.559	.047	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

CD81–CCRCC (DFS)

Open the CCRCC breakdown →